Welcome to our dedicated page for PARK HA BIOLOGICAL TECHNOLOGY SEC filings (Ticker: PHH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Park Ha Biological Technology’s drive to solve stubborn skin issues means its SEC disclosures are packed with R&D data, franchise economics, and consumer-safety discussions rarely seen in mainstream cosmetics reports. If you have ever searched for “Park Ha Biological Technology insider trading Form 4 transactions” or wondered how much revenue its Chinese franchise network contributes, this page is your starting point.
Stock Titan distills every document—whether it’s the “Park Ha Biological Technology quarterly earnings report 10-Q filing” or an 8-K announcing a new skincare patent—into plain language summaries. Our AI pinpoints segment margins, surfaces “Park Ha Biological Technology Form 4 insider transactions real-time,” and links disclosures so you can compare trends without wading through 200 pages. Use it to answer everyday questions like “Park Ha Biological Technology SEC filings explained simply” or to dive deeper with “understanding Park Ha Biological Technology SEC documents with AI.”
Every filing type is here and updated the moment EDGAR posts: the “Park Ha Biological Technology annual report 10-K simplified” for long-term strategy, “Park Ha Biological Technology earnings report filing analysis” for quarter-over-quarter shifts, “Park Ha Biological Technology proxy statement executive compensation” for incentive alignment, and “Park Ha Biological Technology 8-K material events explained” for real-time developments. Monitor “Park Ha Biological Technology executive stock transactions Form 4” to spot buying or selling ahead of product launches, compare R&D intensity against peers, or export data for your valuation model—all from one AI-enhanced hub.
Park Ha Biological Technology Co., Ltd. (symbol: PHH) filed a Form S-8 on 10 July 2025 to register an additional 4,500,000 ordinary shares for issuance under its Amended and Restated 2025 Share Incentive Plan. The amendment lifts the plan’s total share reserve to 7,500,000 shares, incorporating a prior S-8 filed on 3 March 2025. The filing is strictly administrative, containing standard exhibits such as the legal opinion, the amended plan, auditor consent, and filing-fee table. No financial statements, earnings data, or transaction details are provided; the document’s primary purpose is to facilitate future equity awards to employees, directors, and other eligible participants.
FAQ
What is the current stock price of PARK HA BIOLOGICAL TECHNOLOGY (PHH)?
What is the market cap of PARK HA BIOLOGICAL TECHNOLOGY (PHH)?
What is the core business of Park Ha Biological Technology?
How does the company generate its revenue?
What makes the Park Ha brand unique?
How does Park Ha Biological Technology differentiate itself in the competitive skincare market?
What role do franchise alliances play in the company’s approach?
How important are after-sales services to the company?
In what ways does the company ensure the quality of its skincare products?
How does the company compare to other players in the skincare industry?
